Author - Ziad

100 of the world’s most promising start-ups to watch in 2019

Every year, CNBC scans the globe looking for the 100 venture-backed start-ups that have the potential to transform industries and become tomorrow’s household names. Our 2019 Upstart 100 list showcases young start-ups that are building and scaling businesses addressing the rapidly changing technological era we live in. List includes Read more >>

Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage drug development company pioneering transformative medicines that target the endocannabinoid system, today announced continued favorable safety and efficacy outcomes in open-label extensions (OLE) of lenabasum Phase 2 studies in two rare and serious autoimmune diseases: systemic sclerosis (SSc) and dermatomyositis (DM). Read more >>

Hoth Therapeutics Initiates Confirmatory Study for Lupus Treatment

The study is being conducted in partnership with Zylö Therapeutics to confirm that topical administration of Hoth’s AEA-loaded Z-pods™ inhibits the development of CLE lesions in a well-established animal model of lupus. Test protocol requires weekly scoring and a treatment period of 10 weeks after the initial lesions are recorded. Read more >>

eSight 3 Approved on the U.S. Department of Veterans Affairs (VA) Federal Supply Schedule

eSight, a world leader in vision technology, announced the approval of eSight 3 – advanced sight-enhancing glasses for those living with visual impairments — on the United States Department of Veterans Affairs (VA) Federal Supply Schedule (FSS). The registration allows eSight to be included on the FSS through December 2023. Read more >>

Health IT Start-up OmniLife, Inc. Awarded $1.5M National Institutes of Health Small Business Innovation Research Grant

Emerging health IT start-up OmniLife (formerly known as HealthTech Solutions) has received a notice of award from the National Institutes of Health (NIH) for a Small Business Innovation Research (SBIR) Phase II grant totaling $1.5 million. The grant will be used to support research and development of the company’s proprietary software to make organ transplant communication more efficient and effective. Read more >>